Nasdaq requires $4.00 share price for a reverse merger, but what Zalicus did was a 10:1 increasing its pps to $11.40. The reason for that was reduce outstanding shares so that when Zalicus merged with Epirus, Zalicus shareholders only owned 19% of the new company.
Lets say a merger between Amedica & Zimmer resulted in us owning 6% of the new co and Zimmer shareholders owning 94%. That means our share count would need to be reduced 4:1 effectively making our OS ~12mil shares. In this scenario our shares, at $125 pps would be worth $1.5B.
Another possible factor is, the combined synergy of the 2 companies could immediately increase the value of the PPS. So while Zimmer shareholders owned say 94%, the pps could be 137.5 for the new entity representing a 10% premium for current Zimmer holders.
This sort of merger i doubt we see ownership of less than 5% of the new company; would likely trade under Zimmers current ticker.